Drug intelligence / Profile preview

pembrolizumab + temozolomide

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of pembrolizumab (an anti-PD-1 monoclonal antibody) and temozolomide (an alkylating agent). This combination has shown improved efficacy compared to either agent alone in the treatment of advanced melanoma, particularly for acral and mucosal subtypes. The combination works by combining the immune checkpoint inhibition of pembrolizumab with the cytotoxic effects of temozolomide, potentially creating synergistic antitumor activity.

Brand names: Keytruda + Temodar
Other names: pembrolizumab and temozolomideMK-3475 + temozolomideneoadjuvant pembrolizumab and temozolomide

Targets

PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on pembrolizumab + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pembrolizumab + temozolomide.

Explore the full profile